Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Oral P2Y12 receptor antagonists show delayed platelet inhibition in acute myocardial infarction (AMI).
• Selatogrel is a potent, selective, reversible P2Y12 antagonist with rapid action.
• Subcutaneous administration offers a potential alternative for rapid antiplatelet therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of subcutaneous selatogrel in inhibiting platelet aggregation in AMI patients.
• To assess the onset and duration of P2Y12 receptor antagonism following selatogrel administration.
• To determine the dose-response relationship of subcutaneous selatogrel.

Main Methods:

• Randomized trial of 47 AMI patients receiving single subcutaneous doses of selatogrel (8 mg or 16 mg).
• Primary endpoint: P2Y12 reaction units <100 measured by VerifyNow at 30 minutes post-dose.
• Safety assessed up to 48 hours post-injection; platelet aggregation measured at 15, 30, and 60 minutes.

Main Results:

• High response rates observed: 91% for 8 mg and 96% for 16 mg at 30 minutes.
• Rapid platelet inhibition noted at 15 minutes (75% for 8 mg, 91% for 16 mg) and sustained at 60 minutes.
• Selatogrel was well-tolerated with no major bleeding complications.

Conclusions:

• Single-dose subcutaneous selatogrel is safe and effective in AMI patients.
• It induces a rapid, profound, and dose-related antiplatelet response.
• Selatogrel represents a promising therapeutic option for rapid P2Y12 inhibition in AMI.